Time reports that some experts have raised concerns about 23andMe's new direct-to-consumer pharmacogenetic tests.
The market authorization came with a number of caveats and special requirements that 23andMe must follow when selling its PGx tests to consumers.
The project is informing participants of familial hypercholesterolemia genetic test results, and hereditary breast and ovarian cancer, and Lynch syndrome results will follow.
ADx Healthcare is selling an APOE test on the Helix marketplace, while HealthLytix and Dash Genomics are marketing a polygenic hazard score for late-onset Alzheimer's.
23andMe is evaluating how third-party services are impacting customers' experiences and would like to see those services be more complementary to its own efforts.
Indian DTC genomics company Mapmygenome has enlisted Israel-based Digital DNAtix to move its interpretation and personalized medicine services to a blockchain.
Researchers led by MD Anderson’s Karen Lu want to know the most efficient genetic counseling strategy as more people are getting screened for cancer risk genes.
Large-scale population sequencing projects and consumer genomics markets are picking up and oncology continues to be a strong market for Illumina.
With the help of AI, blockchain, and a new cryptocurrency, Nebula wants to give patients more control of their genomic data.
George Church's Nebula is teaming with Hong Kong startup Longenesis to create a secure platform for individuals and biobanks to sell access to their genomes.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.